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Abstract
Background: Accurate assessment of the burden of drug-resistant TB requires systematic efforts to quantify its 
magnitude and trend. In approximately half the countries where resistance has been reported, estimates are based on 
surveys conducted in public sector facilities. However, in locations where a substantial fraction of TB cases seek care 
with private providers, these surveys may not accurately measure resistance in the entire population.
Methods: We describe a mathematical model to investigate biases associated with sampling only from public sector 
cases in India, where TB treatment is offered in both public and private sectors. We then propose and demonstrate a 
weighted estimator as an efficient method for including small numbers of cases from the private sector as a way to 
recover valid estimates of resistance in the population under study.
Results: We find that public sector surveys rarely provide valid estimates of drug-resistance among new and 
retreatment cases. Further, the magnitude and direction of the bias are sensitive to many parameters describing the 
health-seeking behaviours and treatment outcomes of tuberculosis patients, disallowing simple adjustments to 
recover accurate estimates.
Conclusions: In locations where large numbers of tuberculosis patients are diagnosed and treated by private sector 
practitioners who are not typically included in drug resistance surveys, targeted surveys for assessing drug resistance 
are required to validly estimate resistance.
Background
M. tuberculosis resistant to the most potent available
antibiotics threatens the success of global tuberculosis
(TB) control strategies that rely on standard combina-
tions of these drugs [1]. Although resistance to even a sin-
gle first-line agent can reduce the probability of
successful treatment outcome,[2] the most worrisome
disease is resistant to both isoniazid and rifampin (multi-
drug-resistant; MDR). At least 50% of MDR TB patients
treated with standard first-line therapy will fail treatment
and suffer from relapse, chronic disease, or die [3]. Fur-
thermore, the detection of extensively drug resistant
tuberculosis (XDR),[4,5] defined as MDR with additional
resistance to at least a fluoroquinolone and a second-line
injectable antibiotic, heightens concern that increasingly
resistant forms of tuberculosis will undermine the effec-
tiveness of the current arsenal of treatment [6].
Determining the burden of MDR TB requires system-
atic efforts to assess the magnitude and trend of drug-
resistant disease. Since 1994, under the leadership of the
World Health Organization and the International Union
Against Tuberculosis and Lung Diseases (WHO-
IUATLD), four Anti-Tuberculosis Resistance in the
World reports have been published [1,7]. These reports
include data from countries and regions that conduct
either continuous surveillance or periodic surveys for
drug resistant disease. The WHO-IUATLD provides
guidance for the design of such surveys; the principle
requirements are that they 1) include a representative
sample of TB cases from the area under study; 2) differ-
entiate between TB cases that have and have not been
previously exposed to anti-TB antibiotics; and 3) use
standard methods for determining drug resistance and
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utilize approved reference laboratories for quality assur-
ance [8].
In some settings, obtaining representative samples of
specimens from new and retreatment patients is a chal-
lenge. While drug resistance surveys are usually coordi-
nated in the public sector by National Tuberculosis
Programs (NTPs), in areas where a substantial fraction of
patients are treated by private practitioners, many
patients are neither observed in the public sector nor
notified to public authorities. Consequently, surveys con-
ducted exclusively on public sector cases may not reflect
the local burden of resistance.
Here, we describe a simple mathematical model to
investigate potential biases associated with sampling only
from public sector cases in India. We use India as our
motivating example to examine such biases for two rea-
sons. First, India has the highest burden of TB patients in
the world and most patients initially seek care through
private practitioners [9,10]. Second, previous work in
India provides information on differences in diagnostic
and treatment practices in the public and private sector
(each of which are likely to affect the acquisition of drug
resistance) and behavioral data suggesting how TB
patients move between the private and public sectors
[11]. These data are have not been measured and are not
generally available for other countries with both a high
burden of TB and a sizable private sector in which diag-
nosis and treatment of TB is common. We present gen-
eral conditions under which surveys conducted in the
public sector provide valid estimates of drug resistance
among new, retreatment, and combined cases and sug-
gest methods to test whether these conditions are met.
Finally, when exclusion of private sector cases from sur-
v ey s  r es u l ts  i n  b ias ed  e s t i m a t e s  o f  t h e  l oca l  b u r d e n  o f
resistance, we describe an efficient method for including
data from private sector samples to produce valid esti-
mates of resistance.
Private sector providers and drug-resistant tuberculosis in 
India
India has the largest estimated number of incident
(almost 2 million new cases per year) and prevalent TB
cases (almost 3.5 million existing cases), representing
more than 20% of the total worldwide burden of TB [12].
India has invested heavily in extending free access to
high-quality, standardized approaches for diagnosis and
directly observed treatment of TB through public sector
facilities and since 2006 has offered such services in all
districts of the country. Still, surveys indicate that
between 50%-90% of Indian patients first seek care
through a private practitioner; this preference for care
delivered in the private sector exists among patients with
major and minor illnesses, patients residing in rural and
urban areas, and patients from rich and poor households
[9,10,13,14]. Patients may first seek care with for-profit
providers despite the fees associated with such services
because private sector care is viewed as more accessible
and for-profit providers are perceived as more empathic
and better able to dispense high quality drugs [11].
While systematic steps toward improving the quality of
TB diagnosis and treatment in the private sector through
the WHO Public-Private Mix DOTS model (PPM-
DOTS) in India appear promising,[15,16] most care pro-
vided by private practitioners outside of PPM-DOTS pro-
grams remains sub-optimal. Specifically, private
providers outside of PPM-DOTS do not routinely use
sputum smear microscopy to diagnose TB, are more
likely to prescribe non-standard regimens of antibiotics,
and do not directly observe treatment to ensure adher-
ence [13,17,18]. TB patients treated by these private sec-
tor providers are thus less likely to complete treatment
and, if they survive and are not lost from the health care
system entirely, will eventually present for retreatment in
either the public or the private sector [19]. TB patients
treated with inappropriate drugs or for whom adherence
is interrupted also have a higher probability of acquiring
drug resistance while on treatment.
Based on eight surveys conducted between 1995 and
2006 that included a total of 3562 patients, 2.8% of new
T B  p a t i e n t s  w e r e  e s t i m a t e d  t o  b e  i n f e c t e d  w i t h  M D R
strains [1,7]. Only one survey has provided data necessary
to estimate the proportion of incident retreatment cases
that are drug-resistant; in this 2006 survey of 1047
retreatment cases, 17.4% of cases were infected with
MDR strains. Because these drug-resistance surveys are
conducted in public sector facilities, it is not clear
whether these surveys can be used to infer the level of
drug resistance among all TB patients in India. Further-
more, because the risks of successful treatment outcome
and acquired drug resistance differ between public and
private patients and because patients failing therapy in
one sector may switch to the other for retreatment,
understanding the relationship between sector-specific
treatment outcomes and the patterns in which patients
navigate the healthcare system are important for deter-
mining biases associated with drug resistance surveys
conducted only in the public sector.
Methods
Model details and equations
We developed a simple conceptual mathematical frame-
work to evaluate the conditions under which surveys of
drug-resistant TB that are conducted in the public sector
may produce valid estimates of the level of drug-resistant
disease in the entire population. We adopt a difference
equation model in which the population of prevalent TB
cases is divided into eight compartments: new cases of
drug-sensitive TB in the public sector (Z1), new cases ofC
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Table 1: Model input parameters and outputs
Parameter Meaning Notes on values; (allowable ranges)
Inputs
Λ TB incidence rate (new cases) Fixed incidence (value irrelevant)
kFN Fraction of new cases that go to the public sector (0-1)
kRN Fraction of retreatment cases that go to the public sector (0-1)
yt Fraction of new cases that are sensitive 1-qC Where q is the relative transmissibility of resistant compared with sensitive strains (range of q from 0-1; 
assumes no resistant "superbugs") and C (range of C from 0-1) is the proportion of all incident cases with MDR
xS Fraction of new sensitive cases that go to the public sector (0-1)
xR Fraction of new resistant cases that go to the public sector (0-1)
fR, fS
f•N, f•P
Fraction failing treatment among drug resistant and sensitive
Fraction failing treatment in public and private sectors
fS ≤ fR Failure more likely for resistant
and
f•N ≤ f•P Failure as or more likely in private sector
aN,aP Fraction of TB cases in the public and private sectors who acquire 
resistance
(0-1) aN ≤ aP Acquired resistance as or more likely in private sector
l Fraction that are lost to follow-up or die (0-1)
rN Fraction in the public sector that return to the public sector for 
next treatment episode  Retreatment cases more likely to present in public sector
rP Fraction in the private sector that return to the private sector for 
next treatment episode  Retreatment cases more likely to present in public sector
Outputs
rP ≤ 1
2
rP ≤ 1
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A Proportion of new cases with resistant TB
AN Proportion of new cases in public sector with resistant TB
AP Proportion of new cases in private sector with resistant TB
B Proportion of retreatment cases with resistant TB
BN Proportion of retreatment cases in public sector with resistant TB
BP Proportion of retreatment cases in private sector with resistant TB
C Proportion of all cases with resistant TB
CN Proportion of all cases in public sector with resistant TB
CP Proportion of all cases in private sector with resistant TB
Table 1: Model input parameters and outputs (Continued)
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drug-resistant disease in the public sector (Z5), retreat-
ment cases of drug-sensitive disease in the public sector
(Z3), retreatment cases of drug-resistant TB in the public
sector (Z7), plus four corresponding groups of TB
patients which have presented for diagnosis and treat-
ment in the private sector (Z2, Z6, Z4 and Z8) (Figure 1).
Entrance into and transitions between compartments are
governed by the following set of difference equations and
parameters provided in Table 1. In this model, each time
step (t) represents an entire treatment generation; that is,
the interval between when a case is diagnosed and initi-
ates treatment until that case ultimately resolves as cured,
failed, lost to follow-up or died.
We model a constant incidence of tuberculosis (Λ) and
assume that the fraction of incident new cases that is
drug-resistant (1-yt) reflects the relative frequency of
drug-resistant disease in the most recent treatment gen-
eration and the relative transmissibility of drug-resistant
compared with drug-sensitive M. tuberculosis. New
tuberculosis cases that are not cured and do not die or get
lost to follow-up, appear in the next time step (t+1) as
retreatment cases. Previously treated cases can be repeat-
edly re-treated in either the same health sector or switch
to the other health sector. Consistent with data from
India [9-11], we specify that the majority of cases initially
present for treatment in the private sector (yt (1-2xs) + (1-
yt) (1-2xR) > 0), but then move preferentially to the public
sector for retreatment (rp ≤1/2 <rN).
For simplicity, we model only two disease phenotypes:
pan-sensitive TB and MDR TB. We model the acquisition
of the MDR phenotype as occurring during a single
course of treatment (a fraction aN or  aP acquire resis-
tance). While this does not realistically reflect the com-
plexity of sequential acquisition of drug resistance, we
gain qualitative insight into the effect of treatment and
health seeking behavior on the frequency of drug resis-
tance. Additionally, we ignore the possibility that those in
retreatment categories may have been re-infected. We
consider only the effects of standard first-line drug regi-
mens; as such, the proportion of drug-sensitive cases that
are cured exceeds that of drug-resistant cases in both
public and private sectors. In all cases, we assume that a
higher proportion of both drug-sensitive and drug-resis-
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Figure 1 Model structure. The model simultaneously distinguishes 
new TB cases (Z1, Z2, Z5, Z6) from retreatment TB cases (Z3, Z4, Z7, Z8) and 
characterizes the sector of presentation (public = Zodd; private = Zeven) 
and the drug resistance phenotype (sensitive = Z≤4; resistant = Z>4). 
Shaded areas represent classes of drug resistant disease while white ar-
eas represent classes of drug sensitive disease. The equations that de-
scribe transitions between states are provided in the text. The dotted 
arrows represent the acquisition of drug resistance from one treat-
ment episode to the next.
NTP
(PUBLIC SECTOR) PRIVATE SECTOR
FIRST-TIME
TREATMENT
CASES
RETREATMENT
CASES
Z1 Z5 Z2 Z6
Z3
Z4
Z7
Z8
Z1: new DS TB; public
Z2: new DS TB; private
Z3: retreatment DS TB; public
Z4: retreatment DS TB; private
Z5: new DR TB; public
Z6: new DR TB; private
Z7: retreatment DR TB; public
Z8: retreatment DR TB; private
TREATMENT STATES
(DS) (DS)
(DS) (DS)
(DR) (DR)
(DR) (DR)Cohen et al. BMC Public Health 2010, 10:355
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tant cases are successfully  treated in the public sector
than in the private sector.
The fraction of new cases that is resistant reflects both
the relative number of existing infectious cases of drug-
resistant and drug-sensitive TB and the relative transmis-
sibility of drug-resistant compared with drug-sensitive M.
tuberculosis. The fraction of retreatment cases that is
resistant reflects the past incidence of drug-resistance
among new cases, the risk of acquired resistance among
individuals initially infected with drug-sensitive strains,
and the relative effectiveness of treatment for those with
drug-resistant compared to drug-sensitive disease. To
evaluate conditions under which surveys conducted in
the public sector are biased, we report percent bias com-
paring measures of the proportion of disease that is resis-
tant among new and retreatment cases in the public
sector to these same measures in the counterfactual sce-
nario where cases from both the public and private sector
are sampled.
Resistance among new cases
Let C represent the overall prevalence of MDR TB in all
new cases, and AN and  Ap represent the prevalence of
MDR TB in new cases in the public and private sectors,
respectively. We deconstruct A  =  kFNAN  + (1-kFN)Ap,
where kFN is the proportion of new cases that present at
the public sector. What this shows is that in order to
know or estimate A we need knowledge of both AN and
AP,  that is knowledge that can only be assumed, or
obtained from measuring both sectors. This equation can
be rewritten as
It immediately follows that AN is equal to A, and there-
fore an unbiased estimator of AN based on a random sam-
ple from the public sector will unbiasedly estimate A, if
and only if kFN = 1 and, or AN = Ap. First, all new cases go
to the public sector (i.e. kFN = 1) if and only if all new sen-
sitive and all new drug-resistant cases go to the public
sector (i.e. xS = xR = 1). Second, if all new cases do not go
to the public sector (i.e. xS ≠ 1 or xR ≠ 1), then AN must
equal Ap for AN to also equal A. But AN = AP requires that
the fraction of new sensitive cases that go to the public
sector is the same as the fraction of new resistant cases
that go to the public sector (i.e. xS = xR), otherwise, if xS
>xR, then AN <AP which leads to AN <A; and conversely, if
xS <xR, then AN >AP, which leads to AN <A.
Resistance among retreatment cases
Let B represent the overall prevalence of MDR TB in all
retreatment cases, and BN and  BP represent the preva-
lence of MDR TB in retreatment cases in the public and
private sectors respectively. We deconstruct B = k RNBN +
(1-kRN)BP, where kRN is the proportion of retreatment
cases that present at the public sector. This can be rewrit-
ten as
It immediately follows that BN equals B, and an unbi-
ased estimator of BN based on a sample from the public
sector unbiasedly estimates B, if and only if kRN = 1 and,
or BN = BP. Relating this to the parameters in the mathe-
matical model, kRN = 1 requires all individuals to attend
public facilities for retreatment regardless of where previ-
ously treated (i.e. rN = 1 - rP = 1). In general, if an equal
fraction of individuals treated in the public sector and
individuals treated in the private sector seek retreatment
in the public sector (0 ≤ rN = 1 -rP ≤ 1), then it follows
immediately that BN = BP.
Resistance among combined cases
Let C represent the prevalence of MDR TB in all cases.
We deconstruct C in terms of prevalence of drug resis-
tance in new and retreatment cases, C = kNA + (1 - kN)B,
where kN is the proportion of all cases that are new. Pre-
suming that we unbiasedly estimate A and B, these esti-
mates must be weighted by the proportion of new and
retreatment cases in order to unbiasedly estimate C.
Investigating the role of small targeted surveys
In the event that the conditions required for public sec-
tors surveys to return unbiased estimates of resistance
among new or retreatment cases are unlikely to be met,
we recommend a weighted estimator to combine data
from public and private sectors to unbiasedly estimate
MDR TB prevalence in new and retreatment cases. We
assume that the relative burden of cases for public and
private sector are known. Presuming that the MDR TB
surveys are routine activities in the public sector, the data
from these surveys can be augmented with data from tar-
geted surveys in the private sector to efficiently provide
unbiased estimates of the MDR TB prevalence (Case 1)
[20]. In Case 1, nN, the number of samples collected in the
public sector, is fixed by the routine activity, and nP, the
number of samples collected from the private sector, is
determined by either resources or desired level of accu-
racy. For example, suppose on a routine basis, 200 sam-
ples are tested in the public sector (for each type of case)
t o  e s t i m a t e  t h e  p r e v a l e n c e  o f  M D R  T B .  T o  o b t a i n  a n
unbiased estimate of the fraction of all cases with resis-
tance, we can sample an additional 50 individuals in the
private sector. The choice of 50 additional samples is arbi-
AA k A A NF N P N −= − − () ( ) . 1
BB k B B NR N P N −= − − () ( ) . 1Cohen et al. BMC Public Health 2010, 10:355
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trary and was chosen only for illustrative purposes. When
surveys are not routine in the public sector, we propose
an activity that divides the sample between the two sec-
tors (Case 2). In Case 2, the total sample size, n, will be
determined by resource availability and will then be
divided between the public and private sector, so that n =
nN + nP. For example, if resources only allow testing of 50
samples, we may divide the samples evenly between the
public and private sectors.
Results
Resistance among new cases
Figure 2 shows the bias when estimating the prevalence
of MDR TB in new cases solely with information mea-
sured on public sector new cases for a range of xR and xS,
for a system at equilibrium. As shown in the methods
section, in order to unbiasedly estimate overall preva-
lence in new cases with data from public clinics, either i)
all new cases must present in the public sector or ii) the
proportion of all new drug-sensitive cases that present to
the public sector (xS) must be equal to the proportion of
all drug-resistant cases that present to the public sector
(xR). Also, if a higher proportion of new resistant cases
present to the public clinics than new sensitive cases (xR
>xS), then the public sector data will over-estimate the
prevalence of MDR TB in all new cases. However , if a
higher proportion of new sensitive cases present to the
public clinics than new resistant cases (xS >xR), then the
public sector prevalence of MDR TB in new cases will
underestimate the overall prevalence. When the overall
fraction of new cases that present in the public sector is
low (bottom left-hand corner of the figure), the amount
of bias present in surveys of public sector cases is sensi-
tive to even small imbalances between xS and xR.
Resistance among retreatment cases
Figure 3 shows the percent bias when estimating the
prevalence of MDR TB in retreatment cases solely with
information measured on public sector retreatment
cases, for a system at equilibrium. As described in the
methods section, the only sufficient condition that
assures unbiased estimates of the prevalence of MDR TB
in retreatment cases with samples obtained only in public
settings is for failures from the private and public sectors
to present nondifferentially to the public sector for
retreatment (rN = 1-rP). If TB patients failing from the
public and private sectors have different preferences for
Figure 2 Bias in new cases. Percent bias in new cases as a function of 
the fraction of sensitive cases presenting to the public sector (xS) and 
the fraction of resistant cases presenting to the public sector (xR). Blue 
represents parameter space in which public sector surveys overesti-
mate total resistance and red represents parameter space in which 
public sector surveys underestimate total resistance; more saturated 
colors indicate greater bias. The values on the lines indicate percent bi-
as. Results reported for models at equilibrium with aN = 0.1; aP = 0.1; fSN 
= 0.1; fSP = 0.1; fRN = 0.25; fRP = 0.25; l = 0.2; q = 0.6; rN = 0.85; rP = 0.5.
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Figure 3 Bias in retreatment cases. Percent bias in retreatment cases 
as a function of the relative risk of acquired drug resistance and relative 
risk of failure in the private sector. Blue represents parameter space in 
which public sector surveys overestimate total resistance and red rep-
resents parameter space in which public sector surveys underestimate 
total resistance; more saturated colors indicate greater bias. The values 
on the lines indicate percent bias. Results present values at equilibrium 
with aN = 0.1; aP allowed to vary; fSN = 0.1; fSP allowed to vary; fRN = 0.25; 
fRP allowed to vary; l = 0.2; q = 0.6; xR = 0.2; xS = 0.2. The panels represent 
four different scenarios of patient preference for retreatment in public 
or private sector.
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where they seek retreatment (rN ≠ 1-rP), there will almost
certainly be bias in our estimate of drug resistance among
retreatment cases. We find that the direction and magni-
tude of this bias depends on numerous factors including
the relative risk (RR) of acquiring resistance in each sec-
tor, the RR of treatment failure in each sector, and the
sector-specific probability of switching location for
retreatment (Figure 3).
For any fixed value of the RR of failure, there is a greater
fraction of resistance among retreatment cases in the pri-
v a t e  s e c t o r  a s  t h e  R R  o f  a c q u i r e d  r e s i s t a n c e  i n c r e a s e s
within the private sector (trend toward darker red mov-
ing up the y-axis in Figure 3). Furthermore, this bias is
amplified when individuals failing therapy within either
sector remain within that sector for retreatment. Addi-
tional files provide results where we do not assume equal
MDR TB prevalence in new cases (Additional File 1) and
when risk of amplified resistance in the public sector
exceeds that in the private sector (Additional File 2).
Resistance among combined cases
While current guidelines strongly recommend reporting
resistance among new and retreatment cases separately,
some surveys have reported resistance only among new
and retreatment cases combined. For example, in a 1995
survey conducted in the Delhi State of India, a survey of
2240 incident TB cases found 13.3% of these cases were
MDR, but did not identify the fraction resistant within
new and retreatment categories. Figure 4 illustrates a
potential problem with the interpretation of resistance
among combined cases: while it is possible that resistance
among both new and retreatment cases is actually under-
estimated when observing cases in only the public sector,
the observed resistance among combined cases may actu-
ally be an overestimate of resistance in the population.
This is the consequence of retreatment cases (whom we
k n o w  t o  b e  a t  i n c r e a s e d  r i s k  o f  r e s i s t a n c e )  p r e s e n t i n g
preferentially in the public sector where these surveys are
completed and provides an example of Simpson's paradox
[21,22]. This situation arises because the new and retreat-
ment cases are not given the appropriate weights when
only combined cases are reported.
Use of small targeted surveys to eliminate bias
We consider two scenarios to illustrate the potential
applications of this approach. First, in locations where
there is ongoing surveillance for drug resistance in the
public sector, we propose a simple extension to estimate
prevalence of drug resistance in the private sector (Case
1). Second, in areas where public sectors surveys are not
routinely conducted, we propose an efficient sampling
strategy that returns unbiased estimates of resistance for
a fixed sample size (Case 2).
For new cases, the unbiased estimator of MDR preva-
lence is Â = kFN ÂN + (1-kFN) ÂP and the variance for this
estimator is
A similar estimator and variance can be constructed for
retreatment cases. The variances of the estimators differ
between the two scenarios based on the sample sizes
determination.
The impact of using these estimators to correct for
biases depends on both the sector-specific burden of dis-
ease and prevalence of drug resistance. Figures 5a1 and
5b1 depict a plausible scenario for new cases, where we
presume the fraction of cases with drug resistance in the
public sector is 10%, but only 20% of patients initially
receive care in the public sector. Except the special case
when there is also 10% resistance among new cases in the
private sector, the public-sector-only estimates are
biased. The bias increases sharply as resistance in the pri-
vate sector diverges from that in the public sector. For
Case 1, including an additional 50 samples from the pri-
vate sector will eliminate bias in the estimator, with little
compromise in variance. For Case 2, splitting the sample
between the public and private sectors will also eliminate
bias, though the accuracy of the estimators will decrease.
The remaining of the panels of Figure 5 show scenarios
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with increasing fractions of new patients presenting in
the public sector.
A similar situation applies for retreatment cases, where,
for illustration, we assume 30% of MDR TB in the public
sector and 70% of individuals seeking care in the public
sector for retreatment (Figure 6a3 and 6b3). Again, sam-
pling in the private sector eliminates bias from the esti-
mator. The variance of this unbiased estimator is again
smallest when adding resources to ongoing activities
(Case 1), instead of splitting resources between the two
sectors (Case 2). However, we note that for retreatment
cases in India, the bias is likely to be smaller than for new
cases since a smaller proportion of retreatment cases seek
care in the private sector. The remaining of the panels of
Figure 6 show scenarios with different fractions of
retreatment patients presenting in the public sector.
Discussion
Accurate estimates of the burden of MDR tuberculosis
are required to mobilize appropriate resources to combat
this threat to global tuberculosis control. In locations
where patients can access care in various settings, pat-
terns of care-seeking behavior may be related to drug-
resistance. For example, there may be socio-economic
factors that are associated with both infection with drug-
resistant strains and preference for private sector care or,
in areas where second-line treatment for MDR-TB is only
offered in one sector, patients with suspected MDR may
preferentially move to that sector for treatment. There
are few data to suggest how care-seeking behavior may be
associated with drug-resistance within any particular
location, and, even if these associations were well-mea-
sured it would be difficult to generalize these findings to
new settings where resistance and treatment may have a
very different association.
Our model presents a simplified picture of the mecha-
nisms by which drug resistance appears and spreads
within populations and provides insight into the condi-
tions when surveys of drug-resistant disease will be
biased in settings where treatment is offered by both pri-
vate and public practitioners. We find that stringent con-
ditions must be met to assure that resistance among new
and retreatment cases is unbiasedly estimated with public
sector surveys (Figures 2 and 3). Furthermore, especially
when estimating resistance among retreatment cases, it is
difficult to predict either the magnitude or the direction
of this bias. As the data necessary for trying to infer direc-
tion and magnitude of bias is rarely known (and probably
never known with sufficient certainty), we propose a sim-
ple method for using weighted estimators that requires
Figure 5 Comparing estimated resistance in new cases in surveys from public sector only and surveys from public and private sectors. Es-
timates (solid colored lines) and variances (dotted lines) for new cases based on public sector only data (red) and public and private sector data (green), 
assuming different fractions (kFN) of new cases seek care in the public sector, of which 10% have MDR TB. The thick black line represents the actual 
underlying proportion of drug resistance among new cases. The top panels (a1-a4) shows Case 1 (described in the text) where 50 additional samples 
from the private sector are used to create an improved estimate, the bottom panels (b1-b4) shows Case 2 where the total sample is evenly split be-
tween public and private sectors.
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additional information from the private sector to be com-
bined with estimates from public sector surveys to effi-
ciently and validly estimate resistance in the entire
population. In countries with ongoing or routine MDR
TB surveys in the public sector, targeted surveys in the
private sector provide an efficient mechanism to remove
bias. However, even in locations without existing surveil-
lance in the public sector, the stratified sampling estima-
tor can be used to initiate public/private sector surveys
(Figures 5 and 6).
In order to obtain this unbiased estimator of MDR TB
in the new and retreatment cases using the stratified sam-
pling estimator, we assumed that the burden of disease
for each sector is known, in order to directly calculate kFN
and  kRN  (the fraction of new and retreatment cases,
respectively, that go to the public sector). Knowledge of
the burden of TB by sector also would allow for propor-
tionate division of our sample under fixed resource
assumptions (Case 2) in order to minimize the variance of
the estimator. In practical terms, this will require national
TB programs to strengthen relations with private sector
and create mechanisms for reliable notification (or esti-
mation) of new and retreatment disease in both sectors;
this remains a immense challenge, especially in areas with
many types of private providers and hidden populations
of patients receiving informal care. However, as has been
noted previously [15,16], an additional benefit of increas-
ing communication and contact with private providers
promises to improve the standard of care for patients
being treated outside of the public system.
Our conclusions are based on a crude model for the
health seeking behavior of new and retreatment TB cases.
Since we were focused on understanding the relationship
between health seeking behavior and treatment outcomes
of patients on the performance of tuberculosis drug resis-
tance surveys, the model does not include details of the
complex natural history of tuberculosis. For example, we
do not include age-specific differences in the rates of pro-
gression to disease or the risks of reinfection. W e also
assume a fixed time-step over which cases present for
retreatment and that this time-step does not depend on
drug resistance phenotype. Omitting these details allows
us to gain insight into the potential biases associated with
surveys limited to the subset of patients attended to in the
public sector, but limits our ability to assess the dynamic
behavior of this system. Accordingly, we focus our con-
clusions on the system in equilibrium. We note that when
levels of drug resistance are rising or falling, the potential
biases associated with public-sector only surveys will be
even more unpredictable, further supporting our recom-
Figure 6 Comparing estimated resistance in retreatment cases in surveys from public sector only and surveys from public and private sec-
tors. Estimates (solid colored lines) and variances (dotted lines) for retreatment cases based on public sector data only (red) and public and private 
sector data (green), assuming different fractions (kRN) of retreatment cases seek care in the public sector, of which 30% have MDR TB. The thick black 
line represents the actual underlying proportion of drug resistance among new cases. The top panels (a1-a4) shows Case 1 (described in the text) 
where 50 additional samples from the private sector are used to create an improved estimate, the bottom panels (b1-b4) shows Case 2 where the 
total sample is evenly split between public and private sectors.
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mendation that small surveys in the private sector will be
important for understanding the true burden of resis-
tance in locations where patients seek care outside the
public system.
Conclusions
Recent recommendations of the WHO and IUATLD rec-
ognize the need to assess drug resistance within the pri-
vate sector in countries where care is offered in settings
where surveys are not easily implemented,[23] however
these recommendations currently emphasize the need to
first expand and improve surveys within the public sector.
While we agree that public sector surveys remain a cen-
tral activity, we suggest that even small additional surveys
targeted to the private sector would substantially improve
validity of these surveys. In the absence of adequate scale-
up of second-line treatment programs for MDR care in
the public sector, we expect that suspected MDR cases
will increasingly seek care with private providers offering
non-standardized care; this would worsen bias and
increase the likelihood that resistance among retreatment
cases would be underestimated if only measured within
the public sector.
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